IBKR heads into its July 14 earnings print having surrendered 8% on the week, erasing most of the ground that made last month's insider sales look poorly timed.
The stock closed at $87.04 on Tuesday, down from roughly $96 when the previous note was filed on June 22. That's a notable reversal. The prior article flagged that CEO Milan Galik sold $21.5 million worth of shares on May 8, and CFO Paul Brody sold another $7 million on the same day — both at $84.42. Those sales, which looked early at the time, now look considerably better. The stock is barely 3% above where the executives cashed out.
Short positioning has shifted meaningfully since that last note. Short interest has climbed to 3.17% of free float — up from the 2.9% level cited two weeks ago and roughly 35% higher than a month ago. The week-on-week build of 8.8% is the fastest rate of increase in the 30-day window. Despite that accumulation, the lending market remains completely unthreatened: availability is running at 6,762%, meaning there are more than 262 million shares sitting in the lending pool relative to the roughly 14 million currently borrowed. Cost to borrow has tripled on the week to 0.45%, which sounds alarming but remains firmly in "low" territory by any absolute measure. This is a short position being built into a free and easy lending market — not a squeeze setup.
Options traders have actually rotated in the opposite direction from the shorts. The put/call ratio has dropped to 0.56, well below its 20-day average of 0.60 and near the 52-week low of 0.54. That's more than one standard deviation below the mean — a notably call-heavy posture. Two weeks ago, the PCR had spiked to 0.668 on elevated hedging demand. That hedging has now largely unwound, even as the stock has fallen 8%. The divergence is worth watching: shorts are adding, but options buyers are leaning toward calls rather than puts. Positioning looks split rather than aligned.
The Street remains broadly constructive. Analyst targets were refreshed in late April after Q1 results, with Goldman Sachs raising to $98, Barclays to $93, and BMO Capital to $93 — all maintaining positive ratings. The consensus mean target of $89.36 now sits only modestly above the current price of $87.04, meaning the stock has drifted down to within striking distance of where analysts said it was fairly valued two months ago. The PE multiple has compressed to 34.5x, down roughly one point on the week, while the price-to-book of 2.2x has also softened. Factor scores are mixed: analyst recommendation differential ranks in the 93rd percentile, reflecting widespread bullishness, while EPS momentum over 30 and 90 days ranks in the 75th–79th percentile — both solid. The short score of 34.7 is unremarkable at the 48th percentile, consistent with the modest but building short position.
With earnings on July 14, the recent history of post-results moves is worth noting. The last reported quarter saw IBKR fall 1.9% the following day and recover 1.8% over five days. The quarter before that — filed alongside the April 21 announcement — saw a 3.9% one-day drop and a 4.6% five-day decline. Two consecutive down-day reactions after results, even against a backdrop of broadly positive analyst views, is the pattern to carry into the July print.
The setup heading into July 14 is therefore a stock that has pulled back into its analyst price-target band, with shorts adding at a steady clip, options buyers leaning bullish, and insiders who sold near current levels now watching from the sidelines — making the Q2 numbers the single variable that resolves the tension.
See the live data behind this article on ORTEX.
Open IBKR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
